Grifols (GRF) Q4 2024 earnings summary

Executive summary

• Achieved record revenues and adjusted EBITDA in both Q4 and full year 2024, with FY2024 revenue of €7,212m, up 10.3% year-over-year, and Q4 revenue at €1,976m, up 13.6%.

• Adjusted EBITDA reached €1,779m for FY2024 (24.7% margin), up 21.7% year-over-year; Q4 Adjusted EBITDA was €526m (26.6% margin), up 18.6%.

• Strengthened financial position through asset sales, organic deleveraging, improved liquidity, and working capital management; leverage ratio reduced to 4.6x by year-end.

• Advanced innovation pipeline, meeting all 2024 R&D milestones, and received industry sustainability recognition.

• Enhanced corporate governance with board expansion, leadership changes, and new appointments.

Financial highlights

• Q4 revenues nearly EUR 2 billion, up 13.6% year-over-year; full year revenues EUR 7.2 billion, up 10.3%.

• Adjusted EBITDA for Q4 EUR 526 million (margin ~27%); full year EUR 1,779 million (margin 24.7%).

• Net income for FY2024 was EUR 157 million, up 271% year-over-year; Q4 net income was EUR 69 million, up 22%.

• Free cash flow for Q4 EUR 335 million; full year EUR 266 million, exceeding guidance.

• Leverage ratio reduced to 4.6x from 6.8x in Q1; secured leverage at 2.7x.

Outlook and guidance

• 2025 guidance and midterm strategic plan to be detailed at Capital Markets Day.

• Management expects continued improvements in financial and operational performance in 2025, with a focus on sustainable growth, margin expansion, and further deleveraging.

• Confident in ability to sustain growth without significant CapEx for donor/manufacturing expansion in next 3-4 years.